Is AUTO1 CAR T-cell therapy effective in reducing toxicity and enhancing T-cell activation in ALL?

During the 25th Congress of the European Hematology Association (EHA), the ALL Hub spoke to Claire Roddie, University College London, London, UK. We asked, Is AUTO1 chimeric antigen receptor (CAR) T-cell therapy effective in reducing toxicity and enhancing T-cell activation in ALL?

AUTO1 is a CD19-directed CAR T-cell strategy that has demonstrated promising clinical efficacy in the pediatric and young adult setting. However, like other CAR T-cell therapies, there have been safety and toxicity concerns surrounding CD19-directed CAR-Ts. In this interview, Claire Roddie outlines the ongoing study, which aims to optimize the toxicity profile of AUTO1.